aTYR PHARMA INC

LIFE - CIK 0001339970

Market cap$1.67 B

Rank#2240

SEC filings720

aTYR PHARMA INC trades as LIFE and has a market capitalization of $1.67 B, making it the #2240 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $190.00K, down 19.1% from the prior year and net income of -$74.12M. This page tracks aTYR PHARMA INC through 720 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$190.00KFY 2025

Net income (latest FY)-$74.12MFY 2025

Operating cash flow (latest FY)-$61.99MFY 2025

Total assets (latest FY)$93.00MFY 2025

Net margin-39009.5%latest FY

Financial performance

Over the last 6 fiscal years aTYR PHARMA INC's revenue declined from $422.00K to $190.00K, a compound annual decline rate of 12.5%. Net profit margin compressed from -3844.5% to -39009.5% over the same period - every figure below comes from the company's audited annual filings.

LIFE annual revenueView details

Key statistics

Market cap: $1.67 B
Share price (derived)market cap / shares outstanding: $17.06
EPS (diluted)FY 2025: $-0.80
Shares outstandingas of 2026-05-11: 0.10B
Total equityas of 2026-03-31: $57.93M
Return on equity: -127.9%
Cash & equivalentsas of 2026-03-31: $10.01M
Current ratioas of 2026-03-31: 5.78

Latest filings

Filing	Type	Filed
Quarterly report	10-Q	2026-05-15
Major company event	8-K	2026-05-15
Insider trade	4	2026-05-13
Insider trade	4	2026-05-13
Insider trade	4	2026-05-13
Insider trade	4	2026-05-13
Insider trade	4	2026-05-13
Insider trade	4	2026-05-13

Browse the full filing history (720 filings)

Recent press releases

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update2026-05-15
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update | aTyr Pharma
aTyr Pharma to Participate in Upcoming Investor Conferences2026-05-13
aTyr Pharma to Participate in Upcoming Investor Conferences | aTyr Pharma
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting2026-05-11
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting | aTyr Pharma
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update2026-03-05
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update | aTyr Pharma
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2026-02-20
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | aTyr Pharma

Similar companies

The largest companies sharing aTYR PHARMA INC's SEC industry classification (biological products, (no diagnostic substances)).

AMGNAmgen Inc.$183.41 B LIFE vs AMGN

GILDGilead Sciences, Inc.$151.05 B LIFE vs GILD

ARGXargenx SE$53.35 B LIFE vs ARGX

RVMDRevolution Medicines, Inc.$30.65 B LIFE vs RVMD

BIIBBiogen Inc.$28.68 B LIFE vs BIIB

Frequently asked questions

What is aTYR PHARMA INC's market cap?

aTYR PHARMA INC (LIFE) has a market capitalization of $1.67 B as of 2026-06-10, ranking #2240 among US-listed companies.

How much revenue does aTYR PHARMA INC make?

aTYR PHARMA INC reported revenue of $190.00K for fiscal year 2025, a decrease of 19.1% year over year.

Is aTYR PHARMA INC profitable?

In its latest fiscal year aTYR PHARMA INC reported a net loss of $74.12M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.